Philipps University Marburg
169
15
18
113
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.5%
11 terminated/withdrawn out of 169 trials
91.1%
+4.6% vs industry average
8%
13 trials in Phase 3/4
3%
3 of 113 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (169)
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Role: collaborator
Evaluation of a Retrieval Augmented Large Language Model as a Diagnostic Copilot in Rheumatology
Role: lead
Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome
Role: lead
Dynamic Networks in Depression Treatment: Mechanisms of Change in Pharmacological, Psychological and Combined Treatment of Depression
Role: collaborator
Feasibility of Process-based Therapy in a Naturalistic Setting
Role: collaborator
Improved Management of Patients With Recent-Onset Stable Chest Pain
Role: lead
Group Therapy for Major Depression: Comparing Expectation-Focused and Reward-Focused Psychotherapy Approaches
Role: lead
Respiratory Muscles After Inspiratory Muscle Training After COVID-19
Role: collaborator
The Role of Mental Imagery on Approach Motivation and Behavioral Engagement in Social Anxiety
Role: lead
Optimizing Exposure Therapy Via Reward-focused Interventions in Individuals With Public Speaking Anxiety
Role: lead
Enhancing Generalization of Virtual Reality Exposure for Public Speaking Anxiety
Role: lead
The Efficacy of Prospective Mental Imagery in Enhancing Approach Motivation Among Socially Anxious Individuals
Role: lead
Augmentation of Exposure Using Positive Mental Rehearsal in Individuals With Increased Social Anxiety
Role: lead
Optimizing Exposure Using Occasional Aversive Imagery in Spider Fearful Individuals
Role: lead
Ecological Momentary Intervention for Reward in Anhedonia
Role: lead
Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl
Role: collaborator
Prevention-in-PD-Study
Role: collaborator
Enoxolone in Major Depression - Biomarker-outcome Relationship
Role: lead
SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Role: lead
STIMPulseControl Ancillary Speech Study
Role: collaborator